Status:
UNKNOWN
Brimonidine in Rosacea
Lead Sponsor:
Cairo University
Conditions:
Rosacea
Eligibility:
All Genders
18-60 years
Phase:
NA
Brief Summary
Rosacea is a chronic and relapsing inflammatory cutaneous disorder with highly variable prevalence worldwide.
Detailed Description
In our study, we will compare the safety, efficacy, and adverse effects of low-dose oral doxycycline alone versus combined with pulsed dye laser or topical brimonidine in treating erythematotelangiect...
Eligibility Criteria
Inclusion
- Patient with current erythematotelangiectatic rosacea
Exclusion
- \- Pregnant females. 2-Patients on systemic steroids. 3-Patients complaining of other dermatological disorders mainly photosensitive cutaneous disorder.
- 4- Patients receiving any systemic treatment including retinoids for the previous 1 month or any topical treatment for the previous 2 weeks or any laser sessions for the previous 3months for erythematotelangiectatic rosacea at least.
Key Trial Info
Start Date :
May 25 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 15 2022
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT05401422
Start Date
May 25 2022
End Date
September 15 2022
Last Update
June 2 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.